Franklin Lakes, NJ – BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE:BDX), announced today that the U.S. Food and Drug Administration (FDA) has approved the second drug to be offered in the recently launched BD Simplist™ line of ready-to-administer prefilled generic injectables. The second BD Simplist product to launch is Metoclopramide Injection, USP, an injectable antiemetic.

BD Rx launched its first drug – BD Simplist™ Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine – on March 27, 2013. BD Simplist prefilled injectables are designed to help improve patient care and safety by decreasing the number of steps in the traditional vial and syringe injection sequence, reducing the potential risk of medication error.

“After a successful launch of BD Simplist prefilled injectables, we’re excited to be coming out with a second drug that is commonly used by clinicians. This is just the beginning of our new line of prefilled injectable products,” said Mark Sebree, President, BD Rx. “BD has a long-standing reputation for delivering high-quality, high-volume products. Our work at BD Rx is no different, as we bring that same commitment to quality and patient safety to our new work in generic drug manufacturing.”

The potential for medication error exists with every injection. Clinicians perform up to 20 steps in a traditional vial and syringe injection sequence. But with BD Simplist prefilled injectables, the injection sequence is reduced to approximately 12 steps, reducing the potential risk of medication error and allowing for more focus on the patient and less on injection preparation.

The company plans to launch 20 to 30 drugs in its BD Simplist line of products during the next few years and is targeting generic injectables in doses most commonly relied on by clinicians in both the hospital and surgical center settings.

About Metoclopramide Injection, USP

INDICATIONS AND USAGE

Metoclopramide Injection, USP is indicated for:

• the relief of symptoms associated with acute and recurrent diabetic gastric stasis

• prophylaxis of vomiting associated with emetogenic cancer chemotherapy

• the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable.

Metoclopramide Injection, USP also may be used to:

• facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers

• stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine.